Cart
sales@molnova.com
Cirtuvivint
CAS No. 2143917-62-6
Cirtuvivint( —— )
Catalog No. M35134 CAS No. 2143917-62-6
Cirtuvivint (SM08502) is a potent, orally active CDC-like kinase (CLK) inhibitor useful for the study of arthritis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 250 | In Stock |
|
| 10MG | 376 | In Stock |
|
| 25MG | 753 | In Stock |
|
| 50MG | 1051 | In Stock |
|
| 100MG | 1414 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2762 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCirtuvivint
-
NoteResearch use only, not for human use.
-
Brief DescriptionCirtuvivint (SM08502) is a potent, orally active CDC-like kinase (CLK) inhibitor useful for the study of arthritis.
-
DescriptionCirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research.
-
In VitroCirtuvivint (SM08502) inhibits serine and arginine rich splicing factor (SRSF) phosphorylation and disrupted spliceosome activity, which is associated with inhibition of Wnt pathway-related gene and protein expression. Cirtuvivint induces the generation of splicing variants of Wnt pathway genes, suggesting that its mechanism for inhibition of gene expression includes effects on alternative splicing.
-
In VivoOrally administered Cirtuvivint (SM08502) significantly inhibits growth of gastrointestinal tumors and decreased SRSF phosphorylation and Wnt pathway gene expression in xenograft mouse models.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2143917-62-6
-
Formula Weight427.5
-
Molecular FormulaC24H25N7O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (29.24 mM; Ultrasonic (<60°C)
-
SMILESCN1CCN(CC1)c1cc(ccn1)C(=O)Nc1cc2cc(ccc2cn1)-c1cnn(C)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Betty Y Tam, et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 2020 Mar 31;473:186-197.?
molnova catalog
related products
-
G1T38
G1T38 (Lerociclib, G1T 38) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.
-
T025
T025 is a pan CLK inhibitor with Kds of 4.8, 0.096, 6.5, 0.61, and 0.074 nM for CLK1-4, respectively.
-
CDK9-IN-7
CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM).
